Diarrhea - Pipeline Review, H2 2015
Summary
Global Markets Directs, ‘Diarrhea - Pipeline Review, H2 2015, provides an overview of the Diarrheas therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Diarrhea, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA) , route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diarrhea and special features on late-stage and discontinued projects.
Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news and deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens RandD pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Diarrhea
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and RandD brief, licensing and collaboration details and other developmental activities
- The report reviews key players involved in the therapeutics development for Diarrhea and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Diarrhea products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Diarrhea pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective RandD development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Diarrhea
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Diarrhea pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table Of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Diarrhea Overview 8
Therapeutics Development 9
Pipeline Products for Diarrhea - Overview 9
Pipeline Products for Diarrhea - Comparative Analysis 10
Diarrhea - Therapeutics under Development by Companies 11
Diarrhea - Therapeutics under Investigation by Universities/Institutes 13
Diarrhea - Pipeline Products Glance 14
Late Stage Products 14
Clinical Stage Products 15
Early Stage Products 16
Diarrhea - Products under Development by Companies 17
Diarrhea - Products under Investigation by Universities/Institutes 20
Diarrhea - Companies Involved in Therapeutics Development 21
A. Menarini Industrie Farmaceutiche Riunite Srl 21
Ache Laboratorios Farmaceuticos S/A 22
Actelion Ltd 23
Aegis Therapeutics, LLC 24
Akthelia pharmaceuticals ehf 25
Allergan Plc 26
Anatara Lifesciences Limited 27
Ardelyx, Inc. 28
Assembly Biosciences, Inc. 29
Chiesi Farmaceutici SpA 30
Chongqing Zhifei Biological Products Co., Ltd. 31
Cosmo Pharmaceuticals S.p.A 32
DesignMedix, Inc. 33
DiscoveryBiomed, Inc. 34
GlaxoSmithKline Plc 35
GP Pharm, S.A. 36
Helsinn Healthcare S.A. 37
Intercept Pharmaceuticals, Inc. 38
Ipsen S.A. 39
Merck & Co., Inc. 40
Mucosis B.V. 41
Nippon Shinyaku Co., Ltd. 42
Novartis AG 43
Pfizer Inc. 44
Prokarium Limited 45
Protagonist Therapeutics Inc. 46
Rebiotix Inc. 47
Sanofi Pasteur SA 48
Scandinavian Biopharma Holding AB 49
Shire Plc 50
Sigmoid Pharma Limited 51
Summit Therapeutics Plc 52
Synthetic Biologics, Inc. 53
Syntiron LLC 54
Diarrhea - Therapeutics Assessment 55
Assessment by Monotherapy Products 55
Assessment by Target 56
Assessment by Mechanism of Action 58
Assessment by Route of Administration 60
Assessment by Molecule Type 62
Drug Profiles 64
ACE-527 - Drug Profile 64
ACE-920 - Drug Profile 66
ACH-04 - Drug Profile 67
AKT-10081 - Drug Profile 68
ASP-7147 - Drug Profile 69
cadazolid - Drug Profile 70
clostridium difficile vaccine - Drug Profile 71
crofelemer DR - Drug Profile 72
diarrhea vaccine - Drug Profile 74
diarrhea vaccine - Drug Profile 75
Drug for Diarrhea - Drug Profile 76
elsiglutide - Drug Profile 77
eluxadoline - Drug Profile 78
Escherichia coli vaccine - Drug Profile 80
ETEC vaccine - Drug Profile 81
Etvax - Drug Profile 82
fidaxomicin - Drug Profile 84
GVXNSD-133 - Drug Profile 87
Helicobacter pylori [Hel-305] (multivalent) vaccine - Drug Profile 88
ibodutant - Drug Profile 89
IMSUTMR-1501 - Drug Profile 90
infectious diarrhea [serotype H11] (H10407 and E24377A) vaccine - Drug Profile 91
iOWH0-32 - Drug Profile 92
lanreotide acetate - Drug Profile 94
MB-101 - Drug Profile 96
obeticholic acid - Drug Profile 97
octreotide acetate - Drug Profile 100
octreotide acetate MAR - Drug Profile 101
Peptide for Enterocolitis and Infectious Diarrhea - Drug Profile 102
PF-06425090 - Drug Profile 103
prulifloxacin - Drug Profile 104
PZ-7475 - Drug Profile 106
RBX-2660 - Drug Profile 107
RDX-009 - Drug Profile 109
Recombinant Peptide to Activate Mucin 3 for Enterocolitis and Infectious Diarrhea - Drug Profile 110
Recombinant Proteins for Infectious Diarrhea - Drug Profile 112
ridinilazole - Drug Profile 113
rifamycin - Drug Profile 115
Small Molecule for Diarrhea - Drug Profile 117
Small Molecule to Block CFTR for Diarrhoea - Drug Profile 118
Small Molecule to Inhibit EnaC and CFTR for Cystic Fibrosis, Diarrhea and Autosomal Dominant Polycystic Kidney Disease - Drug Profile 119
Small Molecules for Diarrhea - Drug Profile 120
Small Molecules for Microbial Infections - Drug Profile 121
Small Molecules to Inhibit CFTR for Secretory Diarrhea - Drug Profile 122
surotomycin - Drug Profile 123
SYN-004 - Drug Profile 124
Synthetic Peptide for Irritable Bowel Syndrome with Diarrhea - Drug Profile 125
Typhetec - Drug Profile 126
Vaccine for Campylobacter Caused Diarrhea - Drug Profile 127
Vaccine to Target Capsular Vi Polysaccharide Antigen for Traveler's Diarrhea - Drug Profile 129
VP-20621 - Drug Profile 130
Yersinia pestis vaccine - Drug Profile 131
Diarrhea - Recent Pipeline Updates 132
Diarrhea - Dormant Projects 166
Diarrhea - Discontinued Products 168
Diarrhea - Product Development Milestones 169
Featured News & Press Releases 169
Appendix 178
Methodology 178
Coverage 178
Secondary Research 178
Primary Research 178
Expert Panel Validation 178
Contact Us 178
Disclaimer 179
List Of Tables
List of Tables
Number of Products under Development for Diarrhea, H2 2015 13
Number of Products under Development for Diarrhea - Comparative Analysis, H2 2015 14
Number of Products under Development by Companies, H2 2015 15
Number of Products under Investigation by Universities/Institutes, H2 2015 17
Comparative Analysis by Late Stage Development, H2 2015 18
Comparative Analysis by Clinical Stage Development, H2 2015 19
Comparative Analysis by Early Stage Development, H2 2015 20
Products under Development by Companies, H2 2015 21
Products under Development by Companies, H2 2015 (Contd..1) 22
Products under Development by Companies, H2 2015 (Contd..2) 23
Products under Investigation by Universities/Institutes, H2 2015 24
Diarrhea - Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, H2 2015 25
Diarrhea - Pipeline by Ache Laboratorios Farmaceuticos S/A, H2 2015 26
Diarrhea - Pipeline by Actelion Ltd, H2 2015 27
Diarrhea - Pipeline by Aegis Therapeutics, LLC, H2 2015 28
Diarrhea - Pipeline by Akthelia pharmaceuticals ehf, H2 2015 29
Diarrhea - Pipeline by Allergan Plc, H2 2015 30
Diarrhea - Pipeline by Anatara Lifesciences Limited, H2 2015 31
Diarrhea - Pipeline by Ardelyx, Inc., H2 2015 32
Diarrhea - Pipeline by Assembly Biosciences, Inc., H2 2015 33
Diarrhea - Pipeline by Chiesi Farmaceutici SpA, H2 2015 34
Diarrhea - Pipeline by Chongqing Zhifei Biological Products Co., Ltd., H2 2015 35
Diarrhea - Pipeline by Cosmo Pharmaceuticals S.p.A, H2 2015 36
Diarrhea - Pipeline by DesignMedix, Inc., H2 2015 37
Diarrhea - Pipeline by DiscoveryBiomed, Inc., H2 2015 38
Diarrhea - Pipeline by GlaxoSmithKline Plc, H2 2015 39
Diarrhea - Pipeline by GP Pharm, S.A., H2 2015 40
Diarrhea - Pipeline by Helsinn Healthcare S.A., H2 2015 41
Diarrhea - Pipeline by Intercept Pharmaceuticals, Inc., H2 2015 42
Diarrhea - Pipeline by Ipsen S.A., H2 2015 43
Diarrhea - Pipeline by Merck & Co., Inc., H2 2015 44
Diarrhea - Pipeline by Mucosis B.V., H2 2015 45
Diarrhea - Pipeline by Nippon Shinyaku Co., Ltd., H2 2015 46
Diarrhea - Pipeline by Novartis AG, H2 2015 47
Diarrhea - Pipeline by Pfizer Inc., H2 2015 48
Diarrhea - Pipeline by Prokarium Limited, H2 2015 49
Diarrhea - Pipeline by Protagonist Therapeutics Inc., H2 2015 50
Diarrhea - Pipeline by Rebiotix Inc., H2 2015 51
Diarrhea - Pipeline by Sanofi Pasteur SA, H2 2015 52
Diarrhea - Pipeline by Scandinavian Biopharma Holding AB, H2 2015 53
Diarrhea - Pipeline by Shire Plc, H2 2015 54
Diarrhea - Pipeline by Sigmoid Pharma Limited, H2 2015 55
Diarrhea - Pipeline by Summit Therapeutics Plc, H2 2015 56
Diarrhea - Pipeline by Synthetic Biologics, Inc., H2 2015 57
Diarrhea - Pipeline by Syntiron LLC, H2 2015 58
Assessment by Monotherapy Products, H2 2015 59
Number of Products by Stage and Target, H2 2015 61
Number of Products by Stage and Mechanism of Action, H2 2015 63
Number of Products by Stage and Route of Administration, H2 2015 65
Number of Products by Stage and Molecule Type, H2 2015 67
Diarrhea Therapeutics - Recent Pipeline Updates, H2 2015 136
Diarrhea - Dormant Projects, H2 2015 170
Diarrhea - Dormant Projects (Contd..1) , H2 2015 171
Diarrhea - Discontinued Products, H2 2015 172
List Of Figures
List of Figures
Number of Products under Development for Diarrhea, H2 2015 13
Number of Products under Development for Diarrhea - Comparative Analysis, H2 2015 14
Number of Products under Development by Companies, H2 2015 15
Number of Products under Investigation by Universities/Institutes, H2 2015 17
Comparative Analysis by Clinical Stage Development, H2 2015 19
Comparative Analysis by Early Stage Products, H2 2015 20
Assessment by Monotherapy Products, H2 2015 59
Number of Products by Top 10 Targets, H2 2015 60
Number of Products by Stage and Top 10 Targets, H2 2015 60
Number of Products by Top 10 Mechanism of Actions, H2 2015 62
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015 62
Number of Products by Top 10 Routes of Administration, H2 2015 64
Number of Products by Stage and Top 10 Routes of Administration, H2 2015 64
Number of Products by Top 10 Molecule Types, H2 2015 66
Number of Products by Stage and Top 10 Molecule Types, H2 2015 66
